Literature DB >> 21745567

Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).

Jill Norman1.   

Abstract

The age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with progressive fibrosis. Similar to the correlation between tubulointerstitial fibrosis and progression of chronic kidney disease (CKD), in ADPKD, fibrosis has been identified as the most significant manifestation associated with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is known about the mechanisms underlying progressive scarring in ADPKD although some commonality may be anticipated. Current data suggest that fibrosis associated with ADPKD shares at least some of the "classical" features of fibrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs), over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGFβ) but that there are also some unique and stage-specific features. Epithelial changes appear to precede and to drive interstitial changes leading to the proposal that development of fibrosis in ADPKD is biphasic with alterations in cystic epithelia precipitating changes in interstitial fibroblasts and that reciprocal interactions between these cell types drives progressive accumulation of extracellular matrix (ECM). Since fibrosis is a major component of ADPKD it follows that preventing or slowing fibrosis should retard disease progression with obvious therapeutic benefits. The development of effective anti-fibrotic strategies in ADPKD is dependent on understanding the precise mechanisms underlying initiation and progression of fibrosis in ADPKD and the role of the intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney Disease.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745567      PMCID: PMC3166379          DOI: 10.1016/j.bbadis.2011.06.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  124 in total

Review 1.  What is needed for kidney differentiation and how do we find it?

Authors:  L Saxén
Journal:  Int J Dev Biol       Date:  1999       Impact factor: 2.203

Review 2.  Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk.

Authors:  B Geiger; A Bershadsky; R Pankov; K M Yamada
Journal:  Nat Rev Mol Cell Biol       Date:  2001-11       Impact factor: 94.444

Review 3.  Chronic kidney disease growth factors in renal fibrosis.

Authors:  Peter Boor; Jürgen Floege
Journal:  Clin Exp Pharmacol Physiol       Date:  2011-07       Impact factor: 2.557

4.  Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease.

Authors:  T Nakamura; C Ushiyama; S Suzuki; I Ebihara; N Shimada; H Koide
Journal:  Am J Nephrol       Date:  2000 Jan-Feb       Impact factor: 3.754

5.  The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia.

Authors:  P D Wilson; L Geng; X Li; C R Burrow
Journal:  Lab Invest       Date:  1999-10       Impact factor: 5.662

6.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  A possible role for metalloproteinases in renal cyst development.

Authors:  N Obermüller; N Morente; B Kränzlin; N Gretz; R Witzgall
Journal:  Am J Physiol Renal Physiol       Date:  2001-03

8.  Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.

Authors:  Hiroko Togawa; Koichi Nakanishi; Hironobu Mukaiyama; Taketsugu Hama; Yuko Shima; Mayumi Sako; Masayasu Miyajima; Kandai Nozu; Kazuhiro Nishii; Shizuko Nagao; Hisahide Takahashi; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-17

9.  cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.

Authors:  Kazushige Hanaoka; William B Guggino
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

Review 10.  The cell biology of polycystic kidney disease.

Authors:  Hannah C Chapin; Michael J Caplan
Journal:  J Cell Biol       Date:  2010-11-15       Impact factor: 10.539

View more
  63 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

Review 2.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  Disruption of IFT complex A causes cystic kidneys without mitotic spindle misorientation.

Authors:  Julie A Jonassen; Jovenal SanAgustin; Stephen P Baker; Gregory J Pazour
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 4.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

5.  Pals1 Haploinsufficiency Results in Proteinuria and Cyst Formation.

Authors:  Thomas Weide; Beate Vollenbröker; Ulf Schulze; Ivona Djuric; Maria Edeling; Jakob Bonse; Florian Hochapfel; Olga Panichkina; Dirk-Oliver Wennmann; Britta George; Seonhee Kim; Christoph Daniel; Jochen Seggewiß; Kerstin Amann; Wilhelm Kriz; Michael P Krahn; Hermann Pavenstädt
Journal:  J Am Soc Nephrol       Date:  2017-02-02       Impact factor: 10.121

Review 6.  The extracellular matrix and ciliary signaling.

Authors:  Tamina Seeger-Nukpezah; Erica A Golemis
Journal:  Curr Opin Cell Biol       Date:  2012-07-19       Impact factor: 8.382

7.  Inactivation of integrin-β1 prevents the development of polycystic kidney disease after the loss of polycystin-1.

Authors:  Kyung Lee; Sylvia Boctor; Laura M C Barisoni; G Luca Gusella
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

8.  Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.

Authors:  Josephine F Trott; Vicki J Hwang; Tatsuto Ishimaru; Kenneth J Chmiel; Julie X Zhou; Kyuhwan Shim; Benjamin J Stewart; Moe R Mahjoub; Kuang-Yu Jen; Dinesh K Barupal; Xiaogang Li; Robert H Weiss
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-03

9.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

10.  Constitutive renal Rel/nuclear factor-κB expression in Lewis polycystic kidney disease rats.

Authors:  Michelle H T Ta; Kristina G Schwensen; David Liuwantara; David L Huso; Terry Watnick; Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.